Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sertraline: a new antidepressant.

D P Doogan1, V Caillard

  • 1Department of Clinical Research, Pfizer Limited, Sandwich, Kent, U.K.

The Journal of Clinical Psychiatry
|August 1, 1988
PubMed
Summary

Sertraline is a potent serotonin reuptake inhibitor with antidepressant effects and a favorable side-effect profile. It effectively treats depression and prevents recurrence without significant anticholinergic or cardiac issues.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice.

Journal of psychopharmacology (Oxford, England)·2012
Same author

[Comment on: "Lack of insight in schizophrenia: a review. Part I: theoretical concept, clinical aspects and Amador's model" of S. Raffard, S. Bayard, D., Capdevielle, F. Garcia, J.-P. Boulenger et M.-C. Gely-Nargeot].

L'Encephale·2009
Same author

[Evolutionary aspects of bipolar disorder].

L'Encephale·2006
Same author

Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group.

Acta psychiatrica Scandinavica·1999
Same author

The chemotherapy of rodent malaria. LIII. 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane: comparison with some compounds of the artemisinin series.

Annals of tropical medicine and parasitology·1997
Same author

Stage sensitivity of Plasmodium vinckei petteri to quinine, mefloquine, and pyrimethamine.

The Journal of parasitology·1995

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Sertraline is a novel selective serotonin reuptake inhibitor (SSRI).
  • Preclinical and clinical data on sertraline's pharmacological profile and efficacy are reviewed.

Purpose of the Study:

  • To review preclinical, clinical pharmacology, and efficacy data of sertraline.
  • To evaluate sertraline's potency, specificity, and effects on beta-adrenergic receptors.

Main Methods:

  • Review of in vitro and in vivo preclinical studies.
  • Analysis of clinical pharmacology data, including effects on platelet serotonin uptake and psychomotor performance.
  • Evaluation of efficacy data for acute antidepressant effects and prevention of depression recurrence.

Main Results:

  • Sertraline is a potent and specific serotonin uptake inhibitor, up to 10 times more active than similar agents.
  • Chronic dosing leads to beta-adrenergic receptor down-regulation.
  • Sertraline inhibits platelet serotonin uptake with no apparent cardiac effects and a plasma half-life of 25 hours.
  • Doses up to 100 mg show minimal psychomotor effects; higher doses exhibit mild sedation.
  • Effective antidepressant and relapse prevention in the 50-200 mg/day range.
  • Side effects are typical for SSRIs (dry mouth, nausea, diarrhea), lacking anticholinergic and sedative effects of amitriptyline.

Conclusions:

  • Sertraline demonstrates significant antidepressant efficacy and relapse prevention.
  • Its pharmacological profile, including potency, specificity, and side-effect profile, supports its use as a novel SSRI.
  • Sertraline offers a favorable alternative to other antidepressants, particularly amitriptyline.

Related Experiment Videos